ASN's Mission

ASN leads the fight to prevent, treat, and cure kidney diseases throughout the world by educating health professionals and scientists, advancing research and innovation, communicating new knowledge, and advocating for the highest quality care for patients.

learn more

Contact ASN

1401 H St, NW, Ste 900, Washington, DC 20005


The Latest on Twitter

Kidney Week

Abstract: PO0173

Triptolide Treats Renal Tubular Injury Induced by Renal Ischemia-Reperfusion Through Specific Delivery of Kidney-Targeting Nanoplatform

Session Information

  • AKI Mechanisms - 1
    October 22, 2020 | Location: On-Demand
    Abstract Time: 10:00 AM - 12:00 PM

Category: Acute Kidney Injury

  • 103 AKI: Mechanisms


  • Tao, Zeng, Southern Medical University Nanfang Hospital, Guangzhou, Guangdong, China
  • Li, Aiqing, Southern Medical University Nanfang Hospital, Guangzhou, Guangdong, China

Triptolide (TP) has been proved to be effective in the treatment of a variety of kidney diseases. Unfortunately, its clinical application is limited because of its high toxicity and low specificity. Here, we report a novel and safe kidney-targeting nano-platform for specific delivery of TP.


Nano-polymer MNPs-TP was synthesized by encapsulating TP in a mesoscale nanoparticles (MNPs) with kidney targeting ability. MNPs-TP was injected into mice via tail vein to evaluate its toxicity to organs and immune system, and compared with free TP. The targeting and mechanisms of MNPs-TP treatment were explored by organ imaging, Transwell and other experimental methods. Finally, the model of renal ischemia-reperfusion injury (IRI) in mice was established, and the protective effects and mechanisms of TP and MNPs-TP on renal tubules in different concentrations were compared.


Toxicity test showed serious pathological changes in liver,testes and the proportion of CD4+/cd8+ in blood of mice in TP group,while MNPs-TP showed no obvious toxic effect on these organs and immune system. The organ imaging and pharmacokinetic experiments indicated that free TP showed a fast metabolism and no specificity in the distribution of free TP in various organs, while the MNPs-TP showed longer metabolic cycle and clear kidney targeting. Immunofluorescence assay of kidney sections showed that MNP-TP was mainly concentrated in the cytoplasm of renal tubular cells.After administration of TP at the dose of 0.1mg/kg body weight to the IRI mice, the renal function represented by BUN and SCr of IRI mice was alleviated .Down-regulation of p-ERK and NGAL suggested that TP could help protect the renal tubules by down-regulating MEK-ERK pathway and alleviated apoptosis of renal tubules. Free TP at the dose of 0.01mg/kg lacked these protective effects, and surprisingly, MNPs-TP kept the protection,which demonstrated that the effective therapeutic dose of MNPs-TP was significantly lower relative to free TP.


MNPs-TP showed superior therapeutic effect on renal ischemia-reperfusion injury in comparison with TP. Furthermore, MNPs-TP conjugate presented much lower hepatotoxicity and no adverse effect on the immune and genital system. The kidney-targeting MNPs may provide a promising drug delivery platform of hydrophobic drugs for treatment of renal diseases.